BR112013008008A2 - composto, composição farmacêutica e processo para preparar um composto - Google Patents

composto, composição farmacêutica e processo para preparar um composto

Info

Publication number
BR112013008008A2
BR112013008008A2 BR112013008008A BR112013008008A BR112013008008A2 BR 112013008008 A2 BR112013008008 A2 BR 112013008008A2 BR 112013008008 A BR112013008008 A BR 112013008008A BR 112013008008 A BR112013008008 A BR 112013008008A BR 112013008008 A2 BR112013008008 A2 BR 112013008008A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112013008008A
Other languages
English (en)
Inventor
Abdul Rehman Abdul Rauf
Ajay Soni
Manoj Kumar Khera
Venkata P Palle
Viswajanani Sattigeri
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR112013008008A2 publication Critical patent/BR112013008008A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/041,2,3-Triazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
BR112013008008A 2010-09-24 2011-09-26 composto, composição farmacêutica e processo para preparar um composto BR112013008008A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2279DE2010 2010-09-24
PCT/IB2011/054229 WO2012038944A1 (en) 2010-09-24 2011-09-26 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013008008A2 true BR112013008008A2 (pt) 2016-06-21

Family

ID=44903306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008008A BR112013008008A2 (pt) 2010-09-24 2011-09-26 composto, composição farmacêutica e processo para preparar um composto

Country Status (10)

Country Link
EP (1) EP2619179A1 (pt)
JP (1) JP2013538821A (pt)
KR (1) KR20140045287A (pt)
CN (1) CN103249719A (pt)
AU (1) AU2011306398A1 (pt)
BR (1) BR112013008008A2 (pt)
CA (1) CA2812362A1 (pt)
MX (1) MX2013003362A (pt)
SG (1) SG188641A1 (pt)
WO (1) WO2012038944A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2023009682A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962529A (en) 1994-06-22 1999-10-05 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863915A (en) * 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
KR20010072089A (ko) 1998-07-30 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제로서 트리시클릭술폰아미드 및 그의 유도체
US6366675B1 (en) 1999-05-21 2002-04-02 Kohji Toda Sound pressure detecting system
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds

Also Published As

Publication number Publication date
CN103249719A (zh) 2013-08-14
EP2619179A1 (en) 2013-07-31
CA2812362A1 (en) 2012-03-29
WO2012038944A1 (en) 2012-03-29
AU2011306398A1 (en) 2013-05-02
SG188641A1 (en) 2013-04-30
KR20140045287A (ko) 2014-04-16
JP2013538821A (ja) 2013-10-17
MX2013003362A (es) 2013-06-05

Similar Documents

Publication Publication Date Title
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
BR112014003798A2 (pt) método para fabricar um composto, e, composto
BRPI1014547A2 (pt) composto, e, processo para preparar um composto.
BRPI1012018A2 (pt) processo para preparar um composto
BRPI1010933A2 (pt) processo para a preparação de um pó, e, composto
BR112014001418A2 (pt) compostos, processo para a preparação dos compostos, e, uso dos compostos
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BRPI0914674A2 (pt) processo para preparação de um pó
BR112014013354A2 (pt) processo para a preparação de um polímero, composição, composto, e, formulação
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
BR112013002036A2 (pt) processo para preparar um plastificante, plastificante e composição polimérica
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
BR112013007040A2 (pt) "método para preparar um composto e composto"
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BR112014007568A2 (pt) composição farmacêutica, uso e processo para preparar a mesma
BRPI1007654A2 (pt) composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"
BR112012029225A2 (pt) processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BR112012002130A2 (pt) processo para a preparação de composto,e, composto intermediário

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired